Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)

Shun Sasaki, Eiji Oki, Hiroshi Saeki, Takayuki Shimose, Sanae Sakamoto, Qingjiang Hu, Kensuke Kudo, Yasuo Tsuda, Yuichiro Nakashima, Kouji Andou, Yoshito Akagi, Yoshihiro Kakeji, Hideo Baba, Yoshihiko Maehara

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.

Original languageEnglish
Pages (from-to)1204-1213
Number of pages10
JournalInternational Journal of Clinical Oncology
Volume24
Issue number10
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Multicenter Studies
Colorectal Neoplasms
Skeletal Muscle
Sarcopenia
Clinical Trials
Drug Therapy
Therapeutics
Disease-Free Survival
Intra-Abdominal Fat
Subcutaneous Fat
Waist Circumference
Neoplasms
Body Mass Index
Tomography
Databases
Incidence

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response : a pooled analysis of a multicenter clinical trial (KSCC 1605-A). / Sasaki, Shun; Oki, Eiji; Saeki, Hiroshi; Shimose, Takayuki; Sakamoto, Sanae; Hu, Qingjiang; Kudo, Kensuke; Tsuda, Yasuo; Nakashima, Yuichiro; Andou, Kouji; Akagi, Yoshito; Kakeji, Yoshihiro; Baba, Hideo; Maehara, Yoshihiko.

In: International Journal of Clinical Oncology, Vol. 24, No. 10, 01.10.2019, p. 1204-1213.

Research output: Contribution to journalArticle

Sasaki, Shun ; Oki, Eiji ; Saeki, Hiroshi ; Shimose, Takayuki ; Sakamoto, Sanae ; Hu, Qingjiang ; Kudo, Kensuke ; Tsuda, Yasuo ; Nakashima, Yuichiro ; Andou, Kouji ; Akagi, Yoshito ; Kakeji, Yoshihiro ; Baba, Hideo ; Maehara, Yoshihiko. / Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response : a pooled analysis of a multicenter clinical trial (KSCC 1605-A). In: International Journal of Clinical Oncology. 2019 ; Vol. 24, No. 10. pp. 1204-1213.
@article{537b9b9f89614843917d4760452a1df7,
title = "Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A)",
abstract = "Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9{\%}) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.",
author = "Shun Sasaki and Eiji Oki and Hiroshi Saeki and Takayuki Shimose and Sanae Sakamoto and Qingjiang Hu and Kensuke Kudo and Yasuo Tsuda and Yuichiro Nakashima and Kouji Andou and Yoshito Akagi and Yoshihiro Kakeji and Hideo Baba and Yoshihiko Maehara",
year = "2019",
month = "10",
day = "1",
doi = "10.1007/s10147-019-01460-8",
language = "English",
volume = "24",
pages = "1204--1213",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response

T2 - a pooled analysis of a multicenter clinical trial (KSCC 1605-A)

AU - Sasaki, Shun

AU - Oki, Eiji

AU - Saeki, Hiroshi

AU - Shimose, Takayuki

AU - Sakamoto, Sanae

AU - Hu, Qingjiang

AU - Kudo, Kensuke

AU - Tsuda, Yasuo

AU - Nakashima, Yuichiro

AU - Andou, Kouji

AU - Akagi, Yoshito

AU - Kakeji, Yoshihiro

AU - Baba, Hideo

AU - Maehara, Yoshihiko

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.

AB - Background: Sarcopenia or degenerative loss of skeletal muscle mass is related to poor prognosis in patients with cancer. This study aimed to clarify the clinical significance of skeletal muscle loss (SML) during chemotherapy for metastatic colorectal cancer (mCRC). Methods: A total of 249 patients who were secondarily registered in a pooled database of mCRC patients with the first-line systemic chemotherapy and prospectively enrolled in six clinical trials of Kyushu Study Group of Clinical Cancer were included in this study. Skeletal muscle area was calculated from computed tomography images before and 3 and 6 months after treatment. Baseline sarcopenia and SML (cut-off value = 9%) were evaluated. Results: Baseline sarcopenia was observed in 135 of 219 patients who were evaluated before treatment. They tended to be male; older; and have lower body mass index, lower visceral and subcutaneous fat contents, and a lower waist circumference (P < 0.01); however, baseline sarcopenia was not associated with prognosis. SML at 3 months was associated with an incidence of adverse events (P = 0.01), poor objective response rate (ORR) (P < 0.01), and poor progression-free survival (PFS) (P = 0.03), and it was an independent predictive factor for poor ORR (P < 0.01) and PFS (P = 0.04). Conclusion: SML at 3 months after systemic chemotherapy for mCRC was associated with poor treatment response. Thus, clarifying the importance of SML prevention guarantees a more effective chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=85065325729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065325729&partnerID=8YFLogxK

U2 - 10.1007/s10147-019-01460-8

DO - 10.1007/s10147-019-01460-8

M3 - Article

AN - SCOPUS:85065325729

VL - 24

SP - 1204

EP - 1213

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 10

ER -